Login to Your Account



Financings Roundup

Somaxon Backs Silenor Sales Efforts with $45M Financing

By Trista Morrison


Thursday, August 4, 2011
Somaxon Pharmaceuticals Inc. continued to slog through the crowded insomnia market with Silenor (doxepin) during the second quarter, growing net sales to $6.2 million – a 170 percent increase over the $2.3 million sold last quarter, and ahead of the $4 million analysts had expected.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription